<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216839</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001CBR08T</org_study_id>
    <nct_id>NCT01216839</nct_id>
  </id_info>
  <brief_title>Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas</brief_title>
  <official_title>Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidnei Epelman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Santa Marcelina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the Everolimus aim response in children and&#xD;
      adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Everolimus aim response in children and adolescents with refractory and relapsed Rhabdomyosarcoma and other soft tissue sarcomas</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define Everolimus toxicity in this population</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory or Relapsed RMS and Soft Tissue Sarcomas</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor, RAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rhabdomyosarcoma and other soft tissue sarcoma histological confirmation.&#xD;
&#xD;
          -  No option of known curative treatment, neither approved treatment that increases&#xD;
             survival with adequate quality of life.&#xD;
&#xD;
          -  Karnofsky scale ≥ 50 for patients over 16 years and Lansky scale ≥ 50 for patients&#xD;
             under 16 years old.&#xD;
&#xD;
          -  Subjects shouldn't have received antineoplasic therapy &lt; 4 weeks before study&#xD;
             treatment initiation.&#xD;
&#xD;
          -  Adequate hematological function: neutrophil count &gt; 1.500/mm³ and hemoglobin &gt; 8.0&#xD;
             mg/dL.&#xD;
&#xD;
          -  Adequate renal function, as defined below:&#xD;
&#xD;
        Age Maximum serum creatinine (mg/dL) 0 - 29 days 0,4 - 0,7 1 month - 3 years 0,7 4 - 7&#xD;
        years 0,8 8 - 10 years 0,9 11 - 12 years 1,0 13 - 17 years 1,2&#xD;
&#xD;
        ≥ 18 years 1,3&#xD;
&#xD;
          -  Adequate hepatic function: total bilirubin ≤ 1.5 x ULN.&#xD;
&#xD;
          -  Patient and/or legal responsible must sign ICF.&#xD;
&#xD;
          -  Life expectation &gt; 8 weeks.&#xD;
&#xD;
          -  Measurable disease, according to RECIST criteria.&#xD;
&#xD;
          -  For female patients of childbearing age: presence of a negative pregnancy test within&#xD;
             7 days prior to day 0.&#xD;
&#xD;
          -  The patient agrees to use effective contraception if procreative potential exists. Use&#xD;
             of reliable means of contraception (e.g. hormonal contraceptive, patch, vaginal ring,&#xD;
             intrauterine device, physical barrier, abstinence)for subjects of reproductive&#xD;
             potential (male and female) is required during study treatment and for 3 months&#xD;
             following last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction, angina and cerebrovascular accident related to&#xD;
             atherosclerosis.&#xD;
&#xD;
          -  Pulmonary disorder(e.g. FEV1 ou DLCO ≤ 70% from expected).&#xD;
&#xD;
          -  Significant hematologic or hepatic abnormality (transaminases levels &gt; 2.5 x ULN or&#xD;
             serum bilirubin &gt; 1.5 x ULN, hemoglobin &lt; 8 g/dL, platelets &lt; 100.000/mm³, ANC &lt;&#xD;
             1.500/mm³.&#xD;
&#xD;
          -  Has other existing serious medical conditions that could adversely affect the ability&#xD;
             of the patient to be treated in accordance with the protocol.&#xD;
&#xD;
          -  Any condition, therapy, or medical condition, which, in the opinion of the attending&#xD;
             physician could represent a risk for the patient or adversely affect the study&#xD;
             objectives.&#xD;
&#xD;
          -  If female, is pregnant or lactating.&#xD;
&#xD;
          -  Active infection at the moment of recruitment.&#xD;
&#xD;
          -  Previous history of organ transplantation.&#xD;
&#xD;
          -  Recent surgery &lt; 2 months before entering study.&#xD;
&#xD;
          -  Concomitant antineoplasic therapy.&#xD;
&#xD;
          -  Patient received more than one rescue treatment, previously.&#xD;
&#xD;
          -  Previous treatment with mTor inhibitors (ex: sirolimus, temsirolimus, everolimus).&#xD;
&#xD;
          -  Use of investigational drug &lt; 30 days before entering study.&#xD;
&#xD;
          -  Non-controlled hyperlipidaemia: serum cholesterol (fasting) &gt; 300 mg/dL or 7,75 mmol/L&#xD;
             and triglycerides (fasting) &gt; 2,5 x ULN.&#xD;
&#xD;
          -  Non-controlled Diabetes Mellitus defined as: glycemia (fasting) &gt; 1,5 x ULN.&#xD;
&#xD;
          -  Patient with hemorrhagic disorder or using oral anti-vitamin K (except Warfarin in low&#xD;
             doses).&#xD;
&#xD;
          -  Patient with HIV infection.&#xD;
&#xD;
          -  Incapable to perform protocol visits.&#xD;
&#xD;
          -  Another neoplasia for the last 2 years (except squamous or basocellular skin cancer).&#xD;
&#xD;
          -  Hypersensitivity history to rapamycin analogs.&#xD;
&#xD;
          -  Chronic treatment with corticoids (except per oral, topical or local treatment) or&#xD;
             another immunosuppressor agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sidnei Epelman, MD</last_name>
    <phone>+55 11 2522-2472</phone>
    <email>pesquisaoncoped@santamarcelina.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Casa de Saúde Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sidnei Epelman, MD</last_name>
      <phone>+55 11 2522-2472</phone>
      <email>pesquisaoncoped@santamarcelina.org</email>
    </contact>
    <investigator>
      <last_name>Sidnei Epelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Santa Marcelina</investigator_affiliation>
    <investigator_full_name>Sidnei Epelman</investigator_full_name>
    <investigator_title>Director of Pediatric Oncology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

